NASDAQ:EIDX - Eidos Therapeutics News Headlines

$25.68
+0.38 (+1.50 %)
(As of 06/26/2019 09:59 AM ET)
Today's Range
$25.00
Now: $25.68
$25.9788
50-Day Range
$23.83
MA: $28.80
$33.99
52-Week Range
$8.89
Now: $25.68
$34.28
Volume95,667 shs
Average Volume169,722 shs
Market Capitalization$945.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Eidos Therapeutics (NASDAQ EIDX) News Headlines

Source:
DateHeadline
BridgeBio Seeks $225 Million In U.S. IPOBridgeBio Seeks $225 Million In U.S. IPO
seekingalpha.com - June 21 at 3:52 PM
Short Interest in Eidos Therapeutics Inc (NASDAQ:EIDX) Increases By 19.6%Short Interest in Eidos Therapeutics Inc (NASDAQ:EIDX) Increases By 19.6%
www.americanbankingnews.com - June 19 at 5:34 AM
Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare ConferenceEidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - June 18 at 6:13 PM
Eidos Therapeutics Inc (NASDAQ:EIDX) Given Average Rating of "Buy" by AnalystsEidos Therapeutics Inc (NASDAQ:EIDX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 15 at 2:05 AM
-$0.38 EPS Expected for Eidos Therapeutics Inc (NASDAQ:EIDX) This Quarter-$0.38 EPS Expected for Eidos Therapeutics Inc (NASDAQ:EIDX) This Quarter
www.americanbankingnews.com - June 10 at 4:10 PM
Eidos Therapeutics Inc (EIDX) CFO Christine Siu Sells 17,000 SharesEidos Therapeutics Inc (EIDX) CFO Christine Siu Sells 17,000 Shares
www.americanbankingnews.com - June 7 at 6:01 PM
Eidos Therapeutics Inc (EIDX) Insider Sells $316,400.00 in StockEidos Therapeutics Inc (EIDX) Insider Sells $316,400.00 in Stock
www.americanbankingnews.com - June 6 at 8:09 PM
Eidos Therapeutics (EIDX) & Its Peers Head-To-Head SurveyEidos Therapeutics (EIDX) & Its Peers Head-To-Head Survey
www.americanbankingnews.com - June 4 at 12:15 AM
Comparing Eidos Therapeutics (EIDX) & Its CompetitorsComparing Eidos Therapeutics (EIDX) & Its Competitors
www.americanbankingnews.com - June 3 at 10:09 PM
Gene Therapy Parent BridgeBio Set to Go PublicGene Therapy Parent BridgeBio Set to Go Public
finance.yahoo.com - May 31 at 11:46 AM
3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400M3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400M
www.bizjournals.com - May 28 at 11:40 AM
Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?
finance.yahoo.com - May 10 at 12:01 PM
Eidos Therapeutics Reports First Quarter 2019 Financial ResultsEidos Therapeutics Reports First Quarter 2019 Financial Results
www.nasdaq.com - May 8 at 12:07 PM
Eidos Therapeutics misses by $0.01Eidos Therapeutics misses by $0.01
seekingalpha.com - May 8 at 12:07 PM
Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming CatalystsBiotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts
seekingalpha.com - May 7 at 3:53 PM
Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial ResultsEidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
finance.yahoo.com - April 15 at 8:54 AM
Eidos Therapeutics Inc.Eidos Therapeutics Inc.
www.barrons.com - April 12 at 2:00 PM
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 5 at 3:53 PM
RM LAW Announces an Investigation of Eidos Therapeutics, Inc.RM LAW Announces an Investigation of Eidos Therapeutics, Inc.
finance.yahoo.com - April 5 at 3:53 PM
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) InvestigationShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) Investigation
finance.yahoo.com - April 4 at 11:52 AM
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 2 at 4:18 PM
Eidos to restate 2018 financialsEidos to restate 2018 financials
seekingalpha.com - April 2 at 11:30 AM
Eidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities LawsEidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
finance.yahoo.com - April 2 at 11:30 AM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDXEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDX
finance.yahoo.com - April 2 at 11:30 AM
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 2 at 11:30 AM
Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the FirmBragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm
finance.yahoo.com - April 2 at 11:30 AM
Eidos Therapeutics, Inc. Estimate MomentumEidos Therapeutics, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:00 PM
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACCEidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC
www.nasdaq.com - March 18 at 11:23 AM
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific SessionsEidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions
finance.yahoo.com - March 18 at 11:23 AM
Eidos Therapeutics to Present at 31st Annual ROTH ConferenceEidos Therapeutics to Present at 31st Annual ROTH Conference
finance.yahoo.com - March 11 at 8:50 AM
Eidos Therapeutics IncEidos Therapeutics Inc
www.bloomberg.com - March 5 at 5:27 AM
Eidos launches late-stage study of AG10 in ATTR-CMEidos launches late-stage study of AG10 in ATTR-CM
seekingalpha.com - February 27 at 12:22 PM
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month EndpointEidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
finance.yahoo.com - February 27 at 12:22 PM
Eidos Therapeutics webcast Wednesday on late-stage plan for AG10Eidos Therapeutics webcast Wednesday on late-stage plan for AG10
seekingalpha.com - February 25 at 3:55 PM
Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) DesignEidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
finance.yahoo.com - February 25 at 10:47 AM
[$$] Drug Developer BridgeBio Raises $299 Million in Fresh Funding[$$] Drug Developer BridgeBio Raises $299 Million in Fresh Funding
finance.yahoo.com - January 24 at 11:58 AM
Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare ConferenceEidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 10:27 AM
Is Eidos Therapeutics, Inc. (EIDX) A Good Stock To Buy?Is Eidos Therapeutics, Inc. (EIDX) A Good Stock To Buy?
finance.yahoo.com - December 21 at 9:46 AM
Eidos Therapeutics Appoints William Lis to Board of DirectorsEidos Therapeutics Appoints William Lis to Board of Directors
finance.yahoo.com - December 7 at 9:22 AM
Factors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics — New Research Emphasizes Economic Growth
finance.yahoo.com - November 21 at 8:39 AM
Roth Capital Starts Eidos Therapeutics (EIDX) at BuyRoth Capital Starts Eidos Therapeutics (EIDX) at Buy
www.streetinsider.com - November 15 at 8:43 AM
Eidos Therapeutics to Present at Two Upcoming Investor ConferencesEidos Therapeutics to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 14 at 8:26 AM
Eidos up 14% on positive AG10 dataEidos up 14% on positive AG10 data
seekingalpha.com - November 12 at 3:22 PM
Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateEidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 8:21 AM
Eidos Therapeutics to host conference call on November 12 to discuss phase 2 clinical trial results of AG10Eidos Therapeutics to host conference call on November 12 to discuss phase 2 clinical trial results of AG10
seekingalpha.com - October 29 at 9:24 AM
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial ResultsEidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
finance.yahoo.com - October 29 at 9:24 AM
Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin AmyloidosisEidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis
finance.yahoo.com - October 26 at 3:22 PM
Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 20Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 20
www.nasdaq.com - October 6 at 7:33 AM
Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral PresentationEidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
finance.yahoo.com - October 5 at 3:19 PM
Eidos AG10 an Orphan Drug in U.S. for transthyretin amyloidosisEidos' AG10 an Orphan Drug in U.S. for transthyretin amyloidosis
seekingalpha.com - October 4 at 7:33 AM
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Featured Article: What are municipal bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel